Heska (NASDAQ:HSKA) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

HSKA has been the topic of a number of other reports. Canaccord Genuity initiated coverage on Heska in a research report on Thursday, October 5th. They set a “buy” rating and a $115.00 target price on the stock. Zacks Investment Research downgraded Heska from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. B. Riley decreased their target price on Heska from $96.50 to $93.00 and set a “neutral” rating on the stock in a research report on Friday, November 3rd. Finally, Raymond James Financial reissued a “buy” rating on shares of Heska in a research report on Monday, December 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $113.30.

Shares of Heska (NASDAQ HSKA) opened at $79.00 on Friday. Heska has a 1 year low of $66.51 and a 1 year high of $115.00. The firm has a market capitalization of $570.86, a PE ratio of 42.92, a P/E/G ratio of 2.18 and a beta of 0.75.

Heska (NASDAQ:HSKA) last released its earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.03. Heska had a return on equity of 15.35% and a net margin of 10.67%. The business had revenue of $31.40 million for the quarter, compared to the consensus estimate of $36.10 million. During the same period last year, the business earned $0.45 earnings per share. The firm’s revenue for the quarter was down 6.0% compared to the same quarter last year. equities research analysts anticipate that Heska will post 2.03 EPS for the current fiscal year.

In other Heska news, insider Michael J. Mcginley sold 7,826 shares of Heska stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total transaction of $681,957.64. Following the sale, the insider now directly owns 106,771 shares of the company’s stock, valued at $9,304,024.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.70% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HSKA. Neuberger Berman Group LLC boosted its holdings in shares of Heska by 34.2% in the 3rd quarter. Neuberger Berman Group LLC now owns 603,469 shares of the medical research company’s stock worth $53,160,000 after acquiring an additional 153,895 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Heska by 47.0% in the 1st quarter. Vanguard Group Inc. now owns 350,609 shares of the medical research company’s stock worth $36,807,000 after acquiring an additional 112,115 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Heska by 115.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 120,174 shares of the medical research company’s stock worth $12,266,000 after acquiring an additional 64,418 shares in the last quarter. Geneva Advisors LLC boosted its holdings in shares of Heska by 565.4% in the 2nd quarter. Geneva Advisors LLC now owns 75,499 shares of the medical research company’s stock worth $7,706,000 after acquiring an additional 64,153 shares in the last quarter. Finally, Fred Alger Management Inc. boosted its holdings in shares of Heska by 133.8% in the 2nd quarter. Fred Alger Management Inc. now owns 97,229 shares of the medical research company’s stock worth $9,924,000 after acquiring an additional 55,647 shares in the last quarter. 81.98% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Heska (HSKA) Rating Lowered to Sell at BidaskClub” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/09/heska-hska-rating-lowered-to-sell-at-bidaskclub.html.

About Heska

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.